Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
about
Same Data; Different InterpretationsSurrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?New strategies in esophageal carcinoma: promises and problems.Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).Do cancer drugs improve survival or quality of life?Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.Surrogate endpoints in early prostate cancer researchSpeed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical TrialsSurrogate endpoints in advanced sarcoma trials: a meta-analysisThe Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs
P2860
Q31125419-2A1D1ACB-0388-4DE0-91B9-C9E3ADB6B81AQ33921813-29C8E4CE-1795-473A-9E68-459F4D95D017Q39717218-A762F128-959B-47FF-B73D-E5AC22E60E31Q46718088-75457A83-1AE5-478C-A220-113021C77939Q47146633-C7B419A6-B5DF-4CB6-BFFC-CB8A3CB21363Q52668760-8131A4EF-D79D-40B6-8FA7-6B74293DBE73Q57112339-15CDE868-FB9A-4791-826D-446A71F40060Q57173000-A639D77C-C2BC-46E9-9D50-66910CD47872Q57818331-DBB7D731-701B-430A-A634-30F0BD2A289BQ58718992-11986855-105A-4529-B8FE-F3A2C348AE5B
P2860
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Strength of Validation for Sur ...... 's Approval of Oncology Drugs.
@en
Strength of Validation for Sur ...... 's Approval of Oncology Drugs.
@nl
type
label
Strength of Validation for Sur ...... 's Approval of Oncology Drugs.
@en
Strength of Validation for Sur ...... 's Approval of Oncology Drugs.
@nl
prefLabel
Strength of Validation for Sur ...... 's Approval of Oncology Drugs.
@en
Strength of Validation for Sur ...... 's Approval of Oncology Drugs.
@nl
P2860
P1476
Strength of Validation for Sur ...... 's Approval of Oncology Drugs.
@en
P2093
P2860
P356
10.1016/J.MAYOCP.2016.02.012
P407
P50
P577
2016-05-10T00:00:00Z